CoChat

Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis

Open access
Shi, Tiffany, Malik, Astha, Yang vom Hofe, Annika, Matuschek, Louis, Mullen, Mary, Lages, Celine S., Kudira, Ramesh, Singh, Ruchi, Zhang, Wujuan, Setchell, Kenneth D.R., Hildeman, David, Pasare, Chandrashekhar, Wagner, Brandee, Miethke, Alexander G. · 2022 · Science Translational Medicine
Cited by 46

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Immune-mediated bile duct epithelial injury and toxicity of retained hydrophobic bile acids drive disease progression in fibrosing cholangiopathies such as biliary atresia or primary sclerosing cholangitis. Emerging therapies include pharmacological agonists to farnesoid X receptor (FXR), the master regulator of hepatic synthesis, excretion, and intestinal reuptake of bile acids. Unraveling the mechanisms of action of pharmacological FXR agonists in the treatment of sclerosing cholangitis (SC), we found that intestinally restricted FXR activation effectively reduced bile acid pool size but did not improve the SC phenotype in MDR2 −/− mice. In contrast, systemic FXR activation not only lowered bile acid synthesis but also suppressed proinflammatory cytokine production by liver-infiltrating inflammatory cells and blocked progression of hepatobiliary injury. The hepatoprotective activity was linked to suppressed production of IL1β and TNFα by hepatic macrophages and inhibition of T H 1/T H 17 lymphocyte polarization. Deletion of FXR in myeloid cells caused aberrant T H 1 and T H 17 lymphocyte responses in diethoxycarbonyl-1,4-dihydrocollidine–induced SC and rendered these mice resistant to the anti-inflammatory and liver protective effects of systemic FXR agonist treatment. Pharmacological FXR activation reduced IL1β and IFNγ production by liver- and blood-derived mononuclear cells from patients with fibrosing cholangiopathies. In conclusion, we demonstrate FXR to control the macrophage-T H 1/17 axis, which is critically important for the progression of SC. Hepatic macrophages are cellular targets of systemic FXR agonist therapy for cholestatic liver disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abi4354

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 46

Metadata

Authors
Shi, T., Malik, A., Yang vom Hofe, A., Matuschek, L., Mullen, M., Lages, C. S., Kudira, R., Singh, R., Zhang, W., Setchell, K. D. R., Hildeman, D., Pasare, C., Wagner, B., & Miethke, A. G.
Venue
Science Translational Medicine
Published
2022-12-14
Volume
14
Issue
675
Pages
eabi4354-eabi4354
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W4311441289
Cited by
46
References
8
FWCI
4.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis. https://app.cochat.ai/papers/10.1126/scitranslmed.abi4354
The paper
Shi, T., Malik, A., Yang vom Hofe, A., Matuschek, L., Mullen, M., Lages, C. S., Kudira, R., Singh, R., Zhang, W., Setchell, K. D. R., Hildeman, D., Pasare, C., Wagner, B., & Miethke, A. G. (2022). Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abi4354

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.